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SUMMARY 
 
Background: 
In 2007, the University Hospital of Lausanne established the multi-disciplinary Heart 
Transplantation (HTx) team to improve quality of peri-transplant care. Comparison of the 
period 2000-2007 and 2008-2014 showed a decrease of in-hospital mortality from 22.2 to 
16.2% and a reduction of 1-year all cause mortality (ACM) from 25.8% to 18.9% (p=0.612). 
This study investigates whether decreased mortality early post-transplant is associated with 
pre-transplant characteristics of HTx recipients. 
 
 
Methods and Results: 
A total of 140 patients were included with HTx recipients operated between the years 2000 to 
2007 (n=66) and 2008 to 2014 (n=74). Mean age of all patients was 53.5 years (IQR 47.3-
59.8), 112 males, donor/recipient mismatch was present in 38.3% of patients, length of in-
hospital stay was 34 days (IQR 26-61 days); donor age was 41 years (IQR 26-51 years). 
There was no respective difference between patients operated 2000-2007 and 2008-2014. 
HTx recipients operated between the years 2008-2014 less often had dilated cardiomyopathy 
of non-ischemic origin (43.2 vs 63.6%; p=0.024), received more often resynchronization 
therapy (66.2 vs. 33.3%; p=0.0002), AICD treatment (60.8 vs. 21.2%; p<0.0001), or assist 
device treatment (24.3 vs. 9.1%; p=0.030). Mean stay on the waiting list was longer (177 vs. 
110 days; p=0.04). Baseline hemodynamic data, echocardiographic parameters, 
cardiovascular risk factors, comorbidity load, and baseline clinical parameters were not 
different between groups. Diabetes mellitus was a predictor of in-hospital and 1-year ACM in 
patients operated between 2000 and 2007. 
 
 
Conclusion:  
Characteristics of HTx recipients and donors were not significantly different between HTx 
recipients operated between the years 2000 to 2007 and 2008 to 2014 suggesting that 
establishment of a HTx team improved early outcome after HTx.  
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INTRODUCTION: 
 
The care of heart transplant (HTx) patients is complex requiring a finely orchestrated effort to 
improve outcome after transplant. Given the chronic and often complex nature of HTx 
recipients, various disciplines are involved in their care in the early and the late post-
transplant phases. Recognizing the increasing difficulties with post-transplant care, the 
University Hospital of Lausanne established in 2008 a medical care team in order to improve 
efficiencies in pretransplant listing process, operative care, post-transplant inpatient and 
outpatient care, and in the collaboration with heart failure specialist of the University Hospital 
of Geneva. This HTx team consisting of transplant cardiologists with a particular focus on 
heart failure and heart transplantation works as an integral part of the team for solid organ 
transplantation consisting of specialists in cardiac surgery, anesthesiology, intensive care, 
cardiac pathology, infectious diseases, immunology, and nurses trained in pre- and post-
transplant care. Recognizing the difficulty to maintain communication among team members 
and striving for improved efficiencies in our pretransplant listing process, our inpatient care, 
our team meets at regular intervals to assure improved communication to enhance quality of 
patient care. 
To identify the clinical impact of the establishment of the HTx team in 2008, we compared in 
our local HTx population in-hospital mortality and 1-year all-cause mortality between HTx 
recipients with operation in the years 2008 to 2014 and patients who benefited from HTx in 
the years 2000 to 2007. Several reason prompted us to limit the inclusion of HTx recipients 
to the time interval 2000 to 2014 : first, during this period of time at our institution the 
selection criteria for HTx candidates did not change (Mehra  et al., Banner et al.), and 
pharmacological and device-based treatment remained always based on respective 
guidelines (Gronda et al; Jessup et al.; McMurray et al.); second, immunosuppressive 
therapy was guided always by regularly scheduled endomyocardial biopsy with drug 
treatment applied in accordance with recommendations of guidelines in heart transplantation 
(Costanzo et al.) ; third, the time-interval of 1 year was chosen because pre-transplant co-
morbidity may have impact on outcome within the first year post-transplant whereas 
transplant-associated co-morbidity becomes increasingly relevant thereafter (Lund et al.).  
This study investigates whether pre-transplant characteristics of HTx recipients explain the 
decreased mortality observed for the period 2008 to 2014.   
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METHODS : 
 
This study includes all patients who benefited from HTx at the University Hospital of 
Lausanne from the 01.01.2000 to the 31.08.2014. This retrospective analysis was approved 
by the local ethics committee and complies with the Declaration of Helsinki.  
Demographic, clinical, and laboratory data derive from the admission day for HTx and were 
obtained retrospectively from the electronic medical record at the University Hospital of 
Lausanne (M.S.). Donor data were retrieved from the Swiss Organ Allocation System 
(S.O.A.S.) data bank (N.P.). Regarding the graft rejection, the average rejection grade was 
calculated based on myocardial biopsies obtained during the first year after heart transplant. 
All biopsies were graded in accordance using the ISHLT working formulation 2004 (Stewart 
et al.). Echocardiographic data derive from standard transthoracic studies signed by a board-
certified cardiologist at our institution; all exams were performed during index hospitalization. 
Physicians' diagnosis of co-morbidity followed the respective guidelines (Russo et al. ; ESC 
Working group; WHO). A random sample of 20 patients was chosen for control of data 
quality (R.H.). 
 
Statistical analysis : 
Continuous variables are presented as mean (±SD) or median (±interquartile range; IQR). 
Categorical variables are presented as numbers and percentages. Analysis of variance 
compared continuous variables ; and chi2-statistic compared categorical variables.  
The computer software we use was « R », version 3.1.2 (2014-10-31).  
The outcome variables of this study were in-hospital mortality and 1-year all-causes 
mortality. Association between the explanatory variables and the two outcome parameters 
were analyzed for the whole study population and the two study groups. Variables predicting 
in-hospital and one-year mortality were identified from parameters associated with the 
outcome in univariate analysis with a threshold of 10% using the « stepwise backward-
forward » analysis applying the Akaike Information Criteria (AIC) to increase the likelihood of 
the model. The final model was adjusted for age of the donor and the recipient. Survival 
curves were calculated using the Kaplan-Meier method ; comparison of survival curves used 
the log-rank test. All tests were two-sided and used a significance level of p<0.05. Analyses 
were performed using the R statistical software (version R 3.1.0, R development core team). 
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RESULTS: 
 
A total of 140 patients were included into this retrospective analysis of a local cohort of HTx 
recipients. Patients had a mean age of 53.5 years and were predominantly male (80%). The 
length of stay post-transplant was about 34 days without respective differences between 
groups. Time on the waiting list was significantly longer in patients with HTx between the 
years 2008 and 2014 (177 vs. 109 days ; p=0.04). Mean rejection grade of all biopsies 
obtained within the first year post-transplant was 0.4 in the entire cohort and significantly 
different between groups (0.65 vs. 0.20 ; p<0.0001).  Mean donor age was about 41 years in 
the entire cohort and not different between the two groups. 
 
More patients in the first period suffered from dilated cardiomyopathy of non-ischemic origin 
(63.6 vs. 43.2% ; p=0.0249), more patients in the second period were treated with 
resynchronization (66.2 vs. 33.3% ; p=0.0002), AICD (60.8 vs. 21.2% ; p<0.0001), or 
ventricular assist devices (24.3 vs. 9.1% ; p=0.0306).  
 
Mean LVEF was 20%, mean PVR 2.3 Woods Units, mean BMI 24.3 without difference 
between groups. The prevalence of the various cardiovascular risk factors was not 
significantly different between the two periods (entire cohort : HTA : 31.4%, diabetes mellitus 
: 15.7%, history of tobacco use : 45.3%, dyslipidemia : 43.8%, BMI : 24.3 kg/m2). Likewise, 
the rate of co-morbidities such as chronic obstructive pulmonary disease (COPB) and thyroid 
disease were not significantly different between the two groups. 
 
Drug treatment was not significantly different between the two periods except for the use of 
eplerenone which was administered more often in patients of the second period (25.7 vs. 
1.5% ; p=0.0001). Furthermore, laboratory values were not different between groups except 
for the serum iron, which was higher in the second period (12.5 vs. 10.2 umol/l ; p=0.048). 
The prevalence of positive serologies for CMV, EBV, and toxoplasma gondii was not different 
between the two periods both for the recipients and the donors, and the prevalence of 
respective serologies between donor and recipient serologies was not significantly different. 
The number of biopsies procured during the first and second period did not differ (587 vs. 
575 biopsies) whereas the mean rejection grade of patients with HTx during the first period 
was significantly higher when compared to the second period, as calculated by the sum of 
the grade of biopsies with rejection (Stewart et al.) divided the number of successfully 
procured biopsies within the first year (0.70 vs. 0.20, p<0.0001). Histological grading of the 
EMB ≥2R (Stewart et al.) was associated with increased in-hospital in both periods (Chi-
square 4.39 ; p=0.0361 for the first period, Chi-square 3.92 ; p=0.0476 for the second period) 
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but not with 1-year ACM (Chi square 1.97 ; p=0.16 and Chi-square 2.65 ; p=0.1032 
respectively).  
 
In hospital-mortality and 1-year ACM was 21.2% and 22.7% respectively in the first period, 
and 15.1% and 16.4 % respectively in the second period (p=0.4711 and p=0.4708, 
respectively). Univariate analysis showed associations between first-period in-hospital 
mortality and LVEF (OR 1.04 (1.01-1.08 ; p=0.0262), diabetes mellitus (OR 9 (2.07-39.14) ; 
p=0.0034), leucocyte count (OR 0.63 (0.46-0.88) ; p=0.0065), and length of stay (OR 0.91 
(0.86-0.96), p=0.0012).  
 
These associations were not observed in the second period where pre-transplant 
spironolactone treatment was associated with increased in-hospital mortality (OR 10 (1.21-
82.9); p=0.0329). The associations of LVEF, diabetes, mellitus, leucocyte count, and length 
of stay were maintained for 1-year all-cause mortality but not for spironolactone. Multivariate 
statistical analysis controlled for donor and recipient age retained in the first period diabetes 
and length of stay as predictors of in-hospital mortality and 1-year ACM while in the second 
period pre-transplant medication with spironolactone was a predictive for in-hospital mortality 
but not for 1-year ACM.  
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DISCUSSION 
 
This study shows that establishment of a multidisciplinary HTx team with dedicated 
transplant cardiologists is associated with an increase of the number of HTx recipients, a not 
significant decrease of in-hospital mortality and 1-year all causes mortality, and a significant 
decrease of the mean acute cellular rejection (ACR) grade. The decrease of in-hospital and 
1-year mortality and the mean ACR grade was not associated with different pre-transplant 
characteristics of HTx recipients or distinct donor characteristics. 
Various studies have shown that the multidisciplinary team approach increases quality of 
care and decreases length of stay of patients at the intensive care unit (Kim and al.), with 
heart failure (McMurray et al., Wensing et al.), or after HTx (Costanzo et al., Roussel et al.). 
In 2008, the University Hospital of Lausanne established a multidisciplinary team for the care 
of severe heart failure patients and HTx recipients. With regard to heart transplantation, this 
team is part of the multidisciplinary team of the solid organ transplant center combing 
expertise from specialties involved in the complex care of the transplant patient. Pertaining to 
heart transplantation, the multidisciplinary team approach starts with a multidisciplinary 
review committee for the listing process and continues with regular multidisciplinary in-
hospital rounds and an integrated care service for ambulatory follow-up. Roussel et al. have 
already shown that this intervention decreases the time to listing of HTx candidates as well 
as the length of stay and the readmission rate after HTx. However, it remains unclear 
whether the multidisciplinary team approach for in-hospital and integrated ambulatory care 
after discharge decreases the incidence of hard endpoints, in particular in-hospital and early 
mortality after HTx - as reported for patients hospitalized with heart failure (Philbin et al., Mc 
Allister et al.).  
In order to investigate the effect of the multidisciplinary care team on outcome after HTx, this 
study compares the in-hospital and 1-year all causes mortality of HTx recipients with 
operation in the period 2000-2007 (n=66) and 2008 to August 2014 (n=74), assuming a 
strong impact of the multidisciplinary approach on the selection of HTx candidates and the 
immediate and early postoperative outcomes. Basic for this retrospective analysis 
investigating the effect of establishment of a multidisciplinary team approach in HTx is an 
unmodified strategy for guiding immunosuppression after transplant and selecting of HTx 
candidates. In fact, guidance of immunosuppression on the basis of histological grading of 
endomyocardial biopsies procured at regular intervals after HTx had not been modified 
between the two periods. In addition, there was no significant difference in 
immunosuppressive drug treatment between the two groups despite of the advent of 
everolimus after 2003 (Eisen and al.). However, everolimus was administered to only few 
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patients of the period 2008 to 2014. In this group, mortality was similar to mortality in the 
group of patients who benefited from an immunosuppressive treatment with cyclosporine and 
mycophenolate mofetil (Eisen et al.). 
Comparison of the pre-transplant clinical characteristics of HTx recipients showed that more 
patients in the period 2000-2007 had dilated cardiomyopathy of non-ischemic origin, 
otherwise there were no significant differences between groups for recipient age or gender, 
donor age, as well as biological variables, LVEF, pulmonary vascular resistance, BMI, 
cardiovascular risk factors, or co-morbidities. Furthermore, the prevalence of donor/recipient 
mismatch for gender, age, or CMV /EBV serology status was not different, suggesting that 
the profile of patients accepted for HTx listing did not change significantly since the 
establishment of the multidisciplinary team approach. 
We observed a higher in-hospital and 1-year ACM in HTx recipients operated in the period 
2000-2007 when compared with the later period despite of the higher prevalence of dilated 
cardiomyopathy, which has been associated with increased early survival after HTx (Stehlik 
et al.; Zielinski et al.). However, log-rank analysis did not reveal a significant difference of 
survival between the two groups (p=0.612), suggesting nonetheless that the multidisciplinary 
team approach with a specialized HTx team more than compensated the increased risk for 
mortality associated with HTx of patients with ischemic cardiomyopathy. Multivariable 
analysis identified diabetes and length of stay as predictors for mortality in the first period 
while these risk factors were not retained for the second period despite of a similar 
prevalence of diabetes. Various studies show that a multidisciplinary approach for care of 
diabetic patients improves outcome (Norris and al.), therefore, we hypothesize that taking 
care of diabetes by the multidisciplinary team improved outcome in HTx recipients with 
diabetes in the second period. So far, it remains unclear why spironolactone is a predictor of 
in-hospital mortality in the second period despite of almost similar pre-transplant 
administration of this drug in both groups. It could be interesting to investigate more this 
possible relationship in the future. 
A total of 587 EMBs were procured within the first period while 575 biopsies were obtained 
during the second period despite of more patients with HTx during the second period. 
Presence of a histological grade of acute cellular rejection ≥2R was associated with in-
hospital mortality in the early and the late period but not with 1-year ACM despite of a higher 
mean grade of acute cellular rejection in the years 2000-2007. Data from a retrospective 
single-center study show that ≥1 moderate acute cellular rejection is associated with a 
decrease of 10 years survival (Soederlund et al.) suggesting that our follow-up limited to 1 
year post-transplant may have missed the effect of a higher mean acute cellular rejection 
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grade on survival. However, the number of biopsies per patient within the first year post-
transplant as well as the individual mean rejection grade was lower in the later period, 
suggesting that timely executed EMB with subsequent optimal tailoring of therapy was 
facilitated by the multidisciplinary approach. Nevertheless, we cannot exclude that less 
stringent adherence to immunosuppressive drug treatment may have increased the 
incidence of acute cellular rejection in the early period because HTx recipients were 
repetitively trained for comprehensive appreciation of their individual therapy during 
hospitalization and rehabilitation, and outpatient care.  
 
Limitations of the study 
As a limitation to the present study, it should be noted that this single-center study 
investigates retrospectively the effect of a change in patient care without prospectively 
stratified outcome parameters at the time of intervention. The study includes only a small 
number of patients operated in a medium-sized European center, therefore, it is not clear 
whether results also apply to non-European centers. Another weakness of our research is 
that this study does not quantify the change introduced by single action of the 
multidisciplinary approach, but instead focuses on the secondary change such as the 
number of HTx per year, mean acute cellular rejection grade of the individual patient, and 
survival.  
 
CONCLUSION 
Care of the HTx recipient by a multidisciplinary team increases the number of HTx, 
decreases the number of biopsies procured during the first year after HTx, decreases the 
mean rejection grade of the individual patient, and has the potential to reduce both in-
hospital and all cause mortality within the first year after HTx. It remains to be shown whether 
the multidisciplinary team approach may also reduce medium-term and late mortality after 
HTx. 
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LEGENDS : 
 
TABLE 1  
[IQR] = Inter quartile range ; LoS = length of stay ; CMP = cardiomyopathy ; ARVD = 
arrythmogenic right ventricular dysfunction ; HCM = hypertrophic cardiomyopathy ; LVEF = left 
ventricular ejection fraction ; PVR = pulmonary vascular resistance ; PM = pacemaker ; AICD 
= automated internal cardio-defibrillator ; VAD = ventricular assistant device ; BSA = body 
surface area ; BMI = body mass index ; HTA =  arterial hypertension ; COPD = chronic 
obstructive pulmonary disease.  
 
TABLE 2 
ACE = angiotensin converting enzyme ; AT1= angiotensin II receptor type 1. 
 
TABLE 4 
ASAT = alanie-serine transferase; ALAT = alanine-aspartate transferase ; CMV = cytomegalo 
virus; EBV = Ebstein-Barr virus. 
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TABLE 1 RECIPIENTS AND DONOR CHARACTERISTICS : 
 
 
    all 2000-2007 2008-2014 p-value 
 (n=140) (n=66) (n=74) 
RECIPIENT DEMOGRAPHICS : 
Age 53.52 [47.33, 59.8] 53.52 [47.29, 59.57] 53.2 [47.78, 59.6] 0.6637 
Female 28 (20%) 15 (22.7%) 13 (17.6%) 0.5821 
Male 112 (80%) 51 (77.3%) 61 (82.4%) 0.5821 
Time on waiting list (d) 152 [62.75, 386.5] 109.5 [50.25, 313.5] 177 [88.25, 425.75] 0.04 
Mean rejection grade 0.43 0.7 0.1964 <0.0001  
LoS (d) 34 [25.75, 60.5] 32 [25.25, 53] 36 [27.25, 62] 0.2169 
 
 
DONOR DEMOGRAPHICS 
Age 41 [26, 51] 40.5 [26, 51] 43 [29, 51.9] 0.8856 
 
 
ETIOLOGY of CMP      
Ischemic CMP 49 (35.0%) 20 (30.3%) 29 (39.2%) 0.3561 
Dilated CMP 74 (52.9%) 42 (63.6%) 32 (43.2%) 0.0249 
Congenital CMP 18 (12.9%) 9 (13.6%) 9 (12.2%) 0.9942 
ARVD 5 (3.6%) 1 (1.5%) 4 (5.4%) 0.4342 
HCM 14 (10.0%) 7 (10.6%) 7 (9.5%) 1 
Doxocyclin-induced CMP 2 (1.4%) 0 (0%) 2 (2.7%) 0.5275 
Myocarditis 2 (1.4%) 0 (0%) 2 (2.7%) 0.5275 
 
 
DEVICE TREATMENT 
PM 71 (50.7%) 22 (33.3%) 49 (66.2%) 0.0002 
AICD 59 (42.1%) 14 (21.2%) 45 (60.8%) <0.0001 
VAD 24 (17.1%) 6 (9.1%) 18 (24.3%) 0.0306 
 
 
CLINICAL PARAMETERS  
LVEF 20 [15, 25] 20 [15, 25] 22 (15, 30] 0.3883 
PVR 2.3 [1.4, 3.2] 2.63 [1.46, 3.63] 2.15 [1.4, 3.12] 0.3889 
BSA 1.86 [1.7, 2] 1.86 [1.7, 2] 1.88 [1.7, 2] 0.9036 
Size 1.72 [1.65, 1.78] 1.72 [1.64, 1.78] 1.71 [1.65, 1.78] 0.754 
Weight 73.8 [61.9, 83] 71.8 [61.25, 83] 74 [63, 84.25] 0.655 
BMI 24.27 [21.81, 28.07] 23.62 [21.64, 28.07] 24.73 [21.88, 28] 0.596 
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RISK FACTORS / COMORBIDITIES   
Previous thoracic surgery 53 (37.9%) 20 (30.3%) 33 (44.6%) 0.1174 
HTA 44 (31.4%) 17 (25.8%) 27 (36.5%) 0.2369 
Diabetes 22 (15.7%) 10 (15.2%) 12 (16.2%) 1 
History of tobacco abuse 63 (45.3%) 25 (38.5%) 38 (51.4%) 0.1762 
Dyslipidemia 60 (43.8%) 28 (43.8%) 32 (43.8%) 1 
Thyroid disease 18 (12.9%) 5 (7.6%) 13 (17.6%) 0.131 
COPD 12 (8.6%) 4 (6.1%) 8 (10.8%) 0.484 
 
 
 
 
TABLE 2 PRE-TRANSPLANT DRUG TREATMENT 
 
 all 2000-2007 2008-2014 p-value 
 
DRUGS 
Metoprolol 31 (22.1%) 10 (15.2%) 21 (28.4%) 0.0934 
Bisoprolol 7 (5.0%) 4 (6.1%) 3 (4.1%) 0.8765 
Carvedilol 37 (26.4%) 20 (30.3%) 17 (23.0%) 0.4296 
Nebivolol 8 (5.7%) 1 (1.5%) 7 (9.5%) 0.0976 
ACE Inhibitors 68 (48.6%) 37 (56.1%) 31 (41.9%) 0.1323 
AT1-Receptors Blockers 37 (26.4%) 16(24.2%) 21 (28.4%) 0.7173 
Spironolactone 80 (57.1%) 38 (57.6%) 42 (56.8%) 1 
Eplerenone 20 (14.3%) 1 (1.5%) 19 (25.7%) 0.0001 
Torasemide 111 (79.3%) 49 (74.2%) 62 (83.8%) 0.2373 
Hydrochlorthiazid 22 (15.7%) 12 (18.2%) 10 (13.5%) 0.5996 
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TABLE 3 MORTALITY 
 
 all 2000-2007 2008-2014 p-value 
 
1 year-ACM 27 (19.4%) 15 (22.7%) 12 (16.4%) 0.4708 
In-hospital mortality 25 (18%) 14 (21.2%) 11 (15.1%) 0.4711 
  
 
 
 
Figure 1   
Kaplan Meier Survival curves for all patients, and HTx recipients from period 2000-2007  
and 2008-8/2014 
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TABLE 4 PRE-TRANSPLANT RECIPIENT LABORATORY FINDINGS 
 
 
 all 2000-2007 2008-2014 p-value 
Bicarbonate  22.3 [20.7, 23.6] 22.45 [20.95, 24.6] 21.4 [20.25, 23.4] 0.0488 
Creatinine (mmol/l) 111.5 [91.5, 135] 112.5 [90.75, 136,7] 109 [93, 135] 0.6264 
Blood urea nitrogen  (mmol/l) 8.95 [6.8, 12.35] 9.05 [6.93, 13.75] 8.65 [6.65, 11.32] 0.4044 
Bilirubin (mg/l) <6.5 [<10, 15] 11 [<10, 17] <10 [<10, 14] 0.1384 
ASAT (U/l) 31 [23, 41.5] 31 [23, 38] 31 [23,43] 0.7073 
ALAT (U/l) 27 [19, 44.5] 27.5 [20, 46] 27 [19, 42] 0.7338 
CRP (mg/l) 6 [2,14] 13 [0.5, 26.5] 6 [2, 12.5] 0.3399 
Iron (/l) 11.95 [8.4, 17.03] 10.2 [7.7, 14.4] 12.5 [9.15, 18] 0.0479 
Albumin (mg/l 28 [24.75, 34.25] 28 [26,32] 28 [25, 34] 0.9417 
Hemoglobin (g/l) 130 [115, 141.5] 129 [113, 142] 131 [116, 141] 0.4966 
Leucocytes (G/l) 8.1 [6.3, 10] 8.5 [6.4, 9.9] 7.6 [6.12, 10.07] 0.4055 
Thromocytes  (G/l) 212 [170, 258] 213.5 [171.5, 239.2] 209 [167.75, 265.75] 0.8964 
TSH (U/l) 1.64 [0.62, 2.92] 3.01 [2.18, 3.4] 1.42 [0.62, 2.28] 0.4159 
Free T4 (ug/L) 13 [11.75, 16.25] 13 [12.5, 17.5] 13 [11, 16] 0.786 
 
SEROLOGICAL DATA : 
Anti-CMV antibodies 81 (58.7%) 34 (53.1%) 47 (63.5%) 0.2879 
Anti-EBV antibodies 123 (90.4%) 56 (90.3%) 67 (90.5%) 1 
Anti-Toxoplasmosis antibodies 87 (63%) 39 (60.9%) 48 (64.9%) 0.7643 
 
 
DONORS SEROLOGICAL DATA : 
Anti-CMV antibodies 69 (56.6%) 33 (59%) 36 (64.3%) 0.1606 
Anti-EBV antibodies 111 (91%) 60 (90.9%) 51 (91.1%) 1 
Anti-Toxoplasmosis antibodies 87 (63%) 39 (60.9%) 48 (64.9%) 0.7643 
 
 
 
TABLE 5 DONOR / RECIPIENT MATCH 
 
 all 2000-2007 2008-2014 p-value 
Gender mismatch 49 (39.84%) 29 (43.9%) 20 (32.2%) 0.2393 
Age mismatch 53 (43.4%) 34 (51.51%) 20 (35.71%) 0.1169 
CMV mismatch 29 (22.3%) 18 (27.27%) 11 (17.19%) 0.2419 
EBV mismatch 9 (6.71%) 5 (7.94%) 4 (5.63%) 0.8526 
Toxoplasmose mismatch 29 (21.32%) 15 (22.73%) 14 (20.0%) 0.8582 
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TABLE 6 
Univariate analysis for 1 year-ACM 
 
 
 
 
ALL 
 
 
2000-2007 
 
2008-2014 
  
OR 
 
 
p-value 
 
OR 
 
p-value 
 
OR 
 
p-value 
RECIPIENT 
DEMOGRAPHICS 
      
Age 1 (0.97-1.03) 0.84 1 (0.95-1.05) 0.971 1 (0.96-1.04) 0.897 
Gender 0.66 (0.25-1.76) 0.406 0.76 (0.2-2.84) 0.679 0.59 (0.13-2.56) 0.48 
Time on waiting list (d) 1 (1-1) 0.98 1 (1-1) 0.109 1 (1-1) 0.331 
Mean biopsy grade  0.1602  0.1032  0.6872 
LoS 
 
 
0.99 (0.98-1) 0.17 0.92 (0.87-0.97) 0.0013 1 (0.99-1.01) 0.985 
DONOR DEMOGRAPHICS       
Donor age 
 
 
1 (0.97-1.03) 0.847 1 (0.96-1.03) 0.808 1.01 (0.97-1.06) 0.573 
ETIOLOGY of CMP       
Ischemic CMP 1.62 (0.69-3.81) 0.268 2.56 (0.78-8.44) 0.123 1.1 (0.31-3.87) 0.881 
Dilated CMP 0.97 (0.42-2.24) 0.938 0.57 (0.18-1.84) 0.348 1.44 (0.42-4.98) 0.565 
Congenital CMP 1.73 (0.56-5.36) 0.341 1.87 (0.41-8.62) 0.419 1.54 (0.28-8.53) 0.619 
Recipient ARVD 1.04 (0.11-9.68) 0.974 0 (0-Inf) 0.992 1.76 (0.17-18.49) 0.639 
Recipient HCM 
 
0.67 (0.14-3.17) 0.61 1.42 (0.25-8.16) 0.697 0 (0-Inf) 0.991 
DEVICE TREATMENT       
PM 0.74 (0.32-1.73) 0.494 1 (0.29-3.39) 1 0.68 (0.19-2.42) 0.555 
AICD 0.76 (0.32-1.8) 0.527 1.49 (0.39-5.68) 0.558 0.56 (0.16-1.96) 0.368 
VAD 
 
0.8 (0.25-2.57) 0.708 0.66 (0.07-6.1) 0.712 1.02 (0.24-4.27) 0.976 
CLINICAL PARAMETERS       
LVEF 1.02 (0.99-1.05) 0.132 1.04 (1-1.08) 0.0336 0.99 (0.94-1.04) 0.682 
PVR 0.99 (0.66-1.48) 0.958 0.96 (0.53-1.75) 0.89 1.01 (0.58-1.75) 0.969 
BSA 1.09 (0.36-3.29) 0.875 1.96 (0.53-7.18) 0.311 0.34 (0.06-1.75) 0.196 
Size 0.09 (0.01-1.48) 0.0911 0.02 (0-7.94) 0.209 0.1 (0-2.29) 0.151 
Weight 0.98 (0.96-1.01) 0.172 0.98 (0.94-1.02) 0.283 0.99 (0.96-1.02) 0.369 
BMI 
 
 
0.95 (0.87-1.05) 0.313 0.94 (0.82-1.08) 0.416 0.96 (0.85-1.09) 0.545 
RISK FACTORS/ 
COMORBIDITIES 
      
Previous thoracic surgery 1.15 (0.49-2.7) 0.756 1.76 (0.53-5.86) 0.356 0.84 (0.24-2.95) 0.788 
HTA 1.1 (0.45-2.69) 0.835 1.06 (0.29-3.92) 0.927 1.27 (0.36-4.47) 0.714 
Diabetes 2.45 (0.88-6.84) 0.0872 7.83 (1.83-33.47) 0.00547 0.46 (0.05-4) 0.485 
History of tobacco abuse 0.43 (0.17-1.06) 0.0669 0.5 (0.14-1.8) 0.29 0.4 (0.11-1.46) 0.164 
Dyslipemia 1.97 (0.83-4.68) 0.125 1.66 (0.52-5.3) 0.395 2.52 (0.67-9.53) 0.173 
Thyroid.disease 0.81 (0.22-3.02) 0.752 0 (0-Inf) 0.993 1.7 (0.39-7.41) 0.48 
COBP 
 
 
0.82 (0.17-3.96) 0.801 0 (0-Inf) 0.993 1.83 (0.32-10.41) 0.494 
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ALL 
 
 
2000-2007 
 
2008-2014 
  
OR 
 
 
p-value 
 
OR 
 
p-value 
 
OR 
 
p-value 
PRE-TRANSPLANT 
TREATMENT 
      
Metoprolol 1.28 (0.49-3.39) 0.615 0.83 (0.16-4.39) 0.823 2.01 (0.56-7.24) 0.286 
Bisoprolol 1.71 (0.31-9.34) 0.535 3.77 (0.48-29.37) 0.205 0 (0-Inf) 0.994 
Carvedilol 0.42 (0.13-1.3) 0.131 0.5 (0.12-2.01) 0.329 0.26 (0.03-2.14) 0.208 
Nebivolol 0.68 (0.08-5.89) 0.726 20974889.71 (0-
Inf) 
0.991 0 (0-Inf) 0.992 
ACE Inhibitors 0.96 (0.42-2.23) 0.929 0.87 (0.27-2.75) 0.809 0.96 (0.27-3.37) 0.951 
AT1-Receptors Blockers 0.57 (0.2-1.63) 0.293 0.41 (0.08-2.04) 0.273 0.8 (0.19-3.29) 0.753 
Spironolactone 1.37 (0.58-3.26) 0.475 0.56 (0.18-1.8) 0.334 4.84 (0.98-23.94) 0.0533 
Eplerenone 0.42 (0.09-1.92) 0.262 20974889.7 (0-Inf) 0.991 0.22 (0.03-1.81) 0.158 
Torasemide 0.9 (0.33-2.5) 0.847 0.62 (0.18-2.16) 0.448 2.42 (0.28-20.75) 0.42 
Hydrochlorthiazid 
 
 
0.61 (0.17-2.24) 0.458 0.63 (0.12-3.26) 0.582 0.53 (0.06-4.58) 0.56 
PRE-TRANSPLANT 
LABORATORY FINDINGS 
      
Bicarbonate 1.03 (0.88-1.22) 0.693 0.97 (0.79-1.18) 0.735 1.15 (0.86-1.54) 0.35 
Creatinine 1 (0.99-1) 0.299 0.99 (0.98-1.01) 0.379 1 (0.98-1.01) 0.512 
BUN 0.99 (0.93-1.06) 0.833 0.98 (0.9-1.07) 0.71 1 (0.9-1.11) 0.989 
Bilirubin 1.01 (0.98-1.04) 0.395 1 (0.96-1.04) 0.88 1.03 (0.98-1.08) 0.193 
ASAT 1 (1-1.01) 0.335 1 (0.98-1.01) 0.525 1.01 (1-1.01) 0.185 
ALAT 0.99 (0.97-1.01) 0.211 0.98 (0.95-1.01) 0.179 1 (0.97-1.02) 0.773 
CRP 0.99 (0.97-1.02) 0.593 0.93 (0.83-1.04) 0.176 1.01 (0.98-1.04) 0.373 
Iron 0.94 (0.86-1.03) 0.198 0.91 (0.79-1.04) 0.166 0.99 (0.88-1.11) 0.86 
Albumin 0.91 (0.76-1.09) 0.309 0 (0-Inf) 1 0.97 (0.82-1.14) 0.693 
Hemoglobin 1.01 (0.99-1.03) 0.499 1.01 (0.98-1.04) 0.38 1 (0.97-1.04) 0.908 
Leucocyte 0.78 (0.65-0.95) 0.0147 0.62 (0.45-0.86) 0.00456 0.94 (0.75-1.17) 0.565 
Platelets 1 (0.99-1) 0.569 0.99 (0.99-1) 0.131 1 (1-1.01) 0.287 
TSH 0.66 (0.26-1.67) 0.377 1 (0-Inf) 1 0.7 (0.26-1.85) 0.468 
Free T4 
 
 
0.89 (0.66-1.22) 0.477 1 (0-Inf) 1 0.92 (0.7-1.21) 0.563 
RECIPIENTS SEROLOGICAL 
DATA 
      
Anti-CMV antibodies 1.27 (0.53-3.02) 0.591 2.08 (0.62-6.99) 0.235 0.79 (0.22-2.79) 0.714 
Anti-EBV antibodies 1.35 (0.28-6.48) 0.71 1.51 (0.16-14.13) 0.717 1.2 (0.13-10.98) 0.872 
Anti-toxopl. antibodies 0.57 (0.24-1.33) 0.193 0.95 (0.29-3.1) 0.932 0.32 (0.09-1.15) 0.081 
Anti-HBC antibodies 0 (0-Inf) 0.989 0 (0-Inf) 0.992 0 (0-Inf) 0.994 
Anti-HCV antibodies 1 (0.11-9.33) 1 1.64 (0.14-19.5) 0.694 0 (0-Inf) 0.993 
Anti-HSV antibodies 
 
 
 
 
 
 
 
 
 
 
1.16 (0.4-3.42) 0.783 1.11 (0.2-6.05) 0.908 1.07 (0.26-4.44) 0.929 
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ALL 
 
 
2000-2007 
 
2008-2014 
  
OR 
 
 
p-value 
 
OR 
 
p-value 
 
OR 
 
p-value 
DONOR SEROLOGICAL 
DATA 
      
Anti-CMV antibodies 0.66 (0.27-1.59) 0.355 0.59 (0.18-1.91) 0.381 0.83 (0.2-3.37) 0.792 
Anti-EBV antibodies 1.19 (0.24-5.89) 0.831 0.55 (0.09-3.36) 0.52 10636203.07 (0-
Inf) 
0.993 
Anti-toxopl. antibodies 0.9 (0.37-2.21) 0.819 0.82 (0.25-2.67) 0.739 1 (0.25-4.05) 1 
Anti-HBC antibodies 0.6 (0.07-5.25) 0.646 0 (0-Inf) 0.993 4.78 (0.27-83.71) 0.284 
Anti-VZV antibodies 0.29 (0.08-1.05) 0.0593 0.52 (0.09-3.2) 0.482 0.14 (0.02-1.01) 0.0515 
Anti-HSV antibodies 
 
 
1.61 (0.49-5.3) 0.433 1.19 (0.28-4.98) 0.813 2.91 (0.31-27.07) 0.348 
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TABLE 7 
Univariate analysis for in-hospital mortality 
 
 
 
 
ALL 
 
 
2000-2007 
 
2008-2014 
  
OR 
 
 
p-value 
 
OR 
 
p-value 
 
OR 
 
p-value 
RECIPIENT 
DEMOGRAPHICS 
      
Age 1.01 (0.98-1.05) 0.409 1 (0.95-1.04) 0.857 1.03 (0.98-1.09) 0.256 
Gender 0.76 (0.27-2.12) 0.596 0.67 (0.18-2.55) 0.558 0.97 (0.18-5.13) 0.972 
Time on waiting list (d) 1 (1-1) 0.993 1 (1-1) 0.191 1 (1-1) 0.48 
Mean biopsy grade  0.03612  0.04761  0.2482 
LoS 0.99 (0.97-1) 
 
 
0.0929 
 
 
0.91 (0.86-0.96) 
 
 
0.00123 
 
 
1 (0.99-1.01) 
 
 
0.81 
 
 
DONOR DEMOGRAPHICS       
Donor age 
 
 
1 (0.97-1.03) 
 
 
0.946 
 
 
0.99 (0.95-1.03) 
 
 
0.548 
 
 
1.01 (0.97-1.06) 
 
 
0.573 
 
 
ETIOLOGY of CMP       
Ischemic CMP 1.28 (0.53-3.12) 0.584 2.04 (0.6-6.92) 0.255 0.85 (0.22-3.19) 0.805 
Dilated CMP 0.97 (0.41-2.32) 0.954 0.49 (0.15-1.61) 0.237 1.78 (0.49-6.46) 0.383 
Congenital CMP 1.36 (0.41-4.55) 0.617 2.09 (0.45-9.7) 0.346 0.68 (0.08-6) 0.724 
Recipient ARVD 1.15 (0.12-
10.71) 0.905 0 (0-Inf) 0.992 1.97 (0.19-20.84) 0.574 
Recipient HCM 
 0.74 (0.15-3.53) 0.705 1.57 (0.27-9.09) 0.617 0 (0-Inf) 0.991 
DEVICE TREATMENT       
PM 0.89 (0.37-2.12) 0.794 1.14 (0.33-3.94) 0.831 0.9 (0.24-3.41) 0.872 
AICD 0.72 (0.29-1.76) 0.473 1.02 (0.24-4.29) 0.982 0.71 (0.19-2.58) 0.6 
VAD 
 
 
0.9 (0.28-2.89) 
 
 
0.853 
 
 
0.72 (0.08-6.75) 
 
 
0.776 
 
 
1.17 (0.28-5) 
 
 
0.827 
 
 
CLINICAL PARAMETERS       
LVEF 1.02 (0.99-1.05) 0.109 1.04 (1.01-1.08) 0.0262 0.99 (0.93-1.04) 0.674 
PVR 0.99 (0.65-1.49) 0.947 0.96 (0.51-1.84) 0.912 1.01 (0.58-1.75) 0.969 
BSA 1.57 (0.54-4.57) 0.406 1.66 (0.48-5.81) 0.425 1.18 (0.16-8.7) 0.874 
Size 0.43 (0.03-6.34) 0.54 0 (0-1.36) 0.0626 2.48 (0.02-274.33) 0.706 
Weight 0.99 (0.96-1.01) 0.326 0.96 (0.92-1) 0.0791 1 (0.97-1.04) 0.83 
BMI 
 
 
0.97 (0.88-1.07) 
 
 
0.537 
 
 
0.92 (0.8-1.06) 
 
 
0.259 
 
 
1.02 (0.89-1.15) 
 
 
0.809 
 
 
RISK FACTORS/ 
COMORBIDITIES 
      
Previous thoracic surgery 1.35 (0.56-3.24) 0.505 2.04 (0.6-6.92) 0.255 1.01 (0.28-3.67) 0.986 
HTA 1.27 (0.51-3.15) 0.607 1.2 (0.32-4.49) 0.786 1.52 (0.41-5.54) 0.53 
Diabetes 2.78 (0.98-7.83) 0.0534 9 (2.07-39.14) 0.00339 0.52 (0.06-4.53) 0.554 
History of tobacco abuse 0.5 (0.2-1.24) 0.135 0.57 (0.16-2.07) 0.394 0.47 (0.12-1.77) 0.265 
Dyslipemia 2.01 (0.82-4.91) 0.126 1.38 (0.42-4.53) 0.595 3.45 (0.81-14.64) 0.0927 
Thyroid.disease 0.9 (0.24-3.38) 0.876 0 (0-Inf) 0.993 1.95 (0.44-8.65) 0.38 
COBP 0.9 (0.19-4.41) 0.901 0 (0-Inf) 0.993 2.07 (0.36-11.91) 0.413 
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ALL 
 
 
2000-2007 
 
2008-2014 
  
OR 
 
 
p-value 
 
OR 
 
p-value 
 
OR 
 
p-value 
PRE-TRANSPLANT 
TREATMENT 
      
Metoprolol 1.12 (0.41-3.12) 0.822 0.37 (0.04-3.18) 0.363 2.4 (0.64-8.93) 0.193 
Bisoprolol 1.9 (0.35-10.38) 0.461 4.17 (0.53-32.65) 0.174 0 (0-Inf) 0.994 
Carvedilol 0.47 (0.15-1.47) 0.192 0.56 (0.14-2.28) 0.42 0.29 (0.03-2.43) 0.252 
Nebivolol 
0.75 (0.09-6.52) 0.794 
23031251.44 (0-
Inf) 0.991 0 (0-Inf) 0.992 
ACE Inhibitors 1.16 (0.49-2.76) 0.734 1.06 (0.32-3.48) 0.927 1.15 (0.32-4.19) 0.828 
AT1-Receptors Blockers 0.64 (0.22-1.85) 0.411 0.45 (0.09-2.28) 0.336 0.92 (0.22-3.85) 0.905 
Spironolactone 1.44 (0.59-3.53) 0.426 0.47 (0.14-1.55) 0.215 10 (1.21-82.9) 0.0329 
Eplerenone 
0.46 (0.1-2.14) 0.325 
23031251.44 (0-
Inf) 0.991 0.24 (0.03-2.05) 0.194 
Torasemide 1.07 (0.36-3.14) 
 
0.907 
 
0.54 (0.15-1.92) 
 
0.341 
 
25442734.32 (0-
Inf) 
0.993 
 
Hydrochlorthiazid 
 
 
0.68 (0.19-2.51) 
 
 
0.565 
 
 
0.7 (0.13-3.64) 
 
 
0.671 
 
 
0.59 (0.07-5.18) 
 
 
0.633 
 
 
PRE-TRANSPLANT 
LABORATORY FINDINGS 
      
Bicarbonate 0.96 (0.81-1.14) 0.649 0.86 (0.69-1.06) 0.161 1.18 (0.86-1.61) 0.302 
Creatinine 1 (0.99-1) 0.412 0.99 (0.98-1.01) 0.373 1 (0.99-1.01) 0.693 
BUN 1 (0.94-1.07) 0.922 0.99 (0.91-1.08) 0.833 1.01 (0.92-1.12) 0.777 
Bilirubin 1.02 (0.99-1.05) 0.282 1 (0.96-1.04) 0.874 1.03 (0.98-1.08) 0.193 
ASAT 1 (1-1.01) 0.319 1 (0.98-1.01) 0.542 1.01 (1-1.01) 0.185 
ALAT 0.99 (0.97-1.01) 0.246 0.98 (0.95-1.01) 0.217 1 (0.97-1.02) 0.773 
CRP 1 (0.97-1.02) 0.712 0.93 (0.83-1.04) 0.176 1.02 (0.99-1.05) 0.258 
Iron 0.94 (0.86-1.03) 0.201 0.9 (0.77-1.04) 0.148 0.99 (0.88-1.11) 0.86 
Albumin 0.91 (0.76-1.09) 0.309 0 (0-Inf) 1 0.97 (0.82-1.14) 0.693 
Hemoglobin 1 (0.98-1.03) 0.669 1.01 (0.98-1.04) 0.56 1 (0.97-1.04) 0.931 
Leucocyte 0.79 (0.64-0.96) 0.019 0.63 (0.46-0.88) 0.00652 0.94 (0.74-1.18) 0.578 
Platelets 1 (0.99-1) 0.604 0.99 (0.99-1) 0.143 1.01 (1-1.01) 0.272 
TSH 0.66 (0.26-1.67) 0.377 1 (0-Inf) 1 0.7 (0.26-1.85) 0.468 
Free T4 
 
 
0.89 (0.66-1.22) 
 
 
0.477 
 
 
1 (0-Inf) 
 
 
1 
 
 
0.92 (0.7-1.21) 
 
 
0.563 
 
 
RECIPIENTS 
SEROLOGICAL DATA 
      
Anti-CMV antibodies 1.33 (0.54-3.27) 0.53 1.8 (0.53-6.13) 0.347 1.03 (0.27-3.91) 0.963 
Anti-EBV antibodies 2.79 (0.34-
22.54) 0.336 1.36 (0.15-12.81) 0.786 8508962.43 (0-Inf) 0.991 
Anti-toxopl. antibodies 0.58 (0.24-1.39) 0.221 0.82 (0.25-2.72) 0.742 0.4 (0.11-1.46) 0.164 
Anti-HBC antibodies 0 (0-Inf) 0.989 0 (0-Inf) 0.992 0 (0-Inf) 0.994 
Anti-HCV antibodies 1.1 (0.12-10.33) 0.931 1.81 (0.15-21.54) 0.64 0 (0-Inf) 0.993 
Anti-HSV antibodies 
 
 
 
 
 
 
1.43 (0.45-4.58) 
 
 
 
 
 
 
 
 
0.549 
 
 
 
 
 
 
 
 
0.99 (0.18-5.45) 
 
 
 
 
 
 
 
 
0.988 
 
 
 
 
 
 
 
 
1.7 (0.33-8.68) 
 
 
 
 
 
 
 
 
0.524 
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ALL 
 
 
2000-2007 
 
2008-2014 
  
OR 
 
 
p-value 
 
OR 
 
p-value 
 
OR 
 
p-value 
DONOR SEROLOGICAL 
DATA 
      
Anti-CMV antibodies 0.73 (0.3-1.79) 0.495 0.69 (0.21-2.28) 0.548 0.83 (0.2-3.37) 0.792 
Anti-EBV antibodies 
1.13 (0.23-5.58) 0.885 0.5 (0.08-3.06) 0.453 
10636203.07 (0-
Inf) 0.993 
Anti-toxopl. antibodies 0.83 (0.33-2.05) 0.681 0.71 (0.21-2.35) 0.57 1 (0.25-4.05) 1 
Anti-HBC antibodies 0.64 (0.07-5.56) 0.683 0 (0-Inf) 0.993 4.78 (0.27-83.71) 0.284 
Anti-VZV antibodies 0.27 (0.07-0.98) 0.0471 0.47 (0.08-2.89) 0.414 0.14 (0.02-1.01) 0.0515 
Anti-HSV antibodies 
 
 
1.5 (0.45-4.96) 
 
 
0.506 
 
 
1.05 (0.25-4.46) 
 
 
0.945 
 
 
2.91 (0.31-27.07) 
 
 
0.348 
 
 
 
 
 
TABLE 8  MULTIVARIATE ANALYSIS FOR THE PERIOD 2000-2007 : 
                     
  
2000-2007 
IN-HOSPITAL MORTALITY (WITHOUT CONTROLLING 
AGE AND GENDER OF THE RECIPIENT AND DONOR) 
 
z value 
 
Pr(>|z|) 
Recipient LVEF                 2.068 0.03869 
Recipient weight              -2.231 0.02570 
Diabetes mellitus   2.698 0.00697 
Los 
 
-2.449 0.01433 
IN-HOSPITAL MORTALITY (WITH CONTROLLING AGE 
AND GENDER OF THE RECIPIENT AND DONOR) 
  
Recipient LVEF                 1.772 0.0764 
Recipient weight              -2.188 0.0287 
Diabetes mellitus   2.551 0.0107 
Los 
 
-2.413 0.0158 
1-YEAR ACM (WITHOUT CONTROLLING AGE AND 
GENDER OF THE RECIPIENT AND DONOR) 
  
Recipient leucocytes -1.881 0.5992 
Diabetes mellitus 1.977 0.04801 
LoS -2.690 0.00716 
1-YEAR ACM (WITH CONTROLLING AGE AND 
GENDER OF THE RECIPIENT AND DONOR) 
  
Recipient leucocytes -1.909 0.5626 
Diabetes mellitus 2.044 0.04095 
LoS -2.703 0.00687 
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TABLE 9 MULTIVARIATE ANALYSIS FOR THE PERIOD 2008-2014 : 
  
2000-2007 
IN-HOSPITAL MORTALITY (WITHOUT CONTROLLING 
AGE AND GENDER OF THE RECIPIENT AND DONOR) 
 
z value 
 
Pr(>|z|) 
Spironolactone 
                 
2.134 0.032863 
IN-HOSPITAL MORTALITY (WITH CONTROLLING AGE 
AND GENDER OF THE RECIPIENT AND DONOR) 
  
Spironolactone     
             
1.604 0.1087 
1-YEAR ACM (WITHOUT CONTROLLING AGE AND 
GENDER OF THE RECIPIENT AND DONOR) 
  
Spironolactone 
 
1.933 0.053290 
1-YEAR ACM (WITH CONTROLLING AGE AND 
GENDER OF THE RECIPIENT AND DONOR) 
  
Spironolactone 1.604 0.1087 
 
 
 
 
 
 
 
 
